ArticleFrontiers in oncology2026
Efficacy, safety, and survival outcomes of radiotherapy combined with nimotuzumab following induction chemotherapy in locally advanced head and neck cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy, safety, and impact on survival of adding nimotuzumab to radiotherapy after induction chemotherapy in patients with locally advanced head and neck cancer (HNC). Methods: This retrospective cohort study included 313 patients with locally advanced HNC treated at a tertiary hospital between 2019 and 2022. Patients were divided into an observation group (n=145), receiving radiotherapy combined with nimotuzumab after induction chemotherapy, and a control group (n=168), receiving radiotherapy alone after induction chemotherapy. Baseline characteristics, short-term efficacy (assessed using RECIST 1.1 criteria, including complete response [CR] and partial response [PR]), overall survival (OS), progression-free survival (PFS), and adverse events were compared between the two groups, and a primary analysis restricted to nasopharyngeal carcinoma (NPC) patients was performed, as NPC comprised the majority of the cohort, to more accurately assess the survival benefits of nimotuzumab in this specific subgroup. Univariate and multivariate analyses were conducted to identify prognostic factors. Results: The observation group demonstrated a significantly higher complete response rate (41.38% Conclusion: The addition of nimotuzumab to radiotherapy following induction chemotherapy significantly improves tumor response rates and long-term survival in patients with locally advanced head and neck cancer, without increasing severe treatment-related toxicity. Given that nasopharyngeal carcinoma constituted the majority of the cohort, this combination regimen represents a particularly promising therapeutic strategy for nasopharyngeal carcinoma. However, because only a small number of non-nasopharyngeal head and neck cancers were included, the observed overall survival benefit should not be generalized to non-nasopharyngeal head and neck cancers, and further prospective studies in more homogeneous populations are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.